Uncategorized

Lupin Digital Health Revealed the Findings of the First Digital Therapeutics Research with ACS Patients

Lupin Digital Health

Lupin Digital Health released the findings of a first-of-its-kind study in India, showing the efficacy of digital therapeutics (DTx) among patients with acute coronary syndrome (ACS) and post-percutaneous coronary interventions. Lupin Digital Health is India’s first evidence-based digital therapeutics platform. The study’s results were presented in Chennai at the India Live 2023 conference. The only evidence-based holistic heart care program in India, Lyfe, was recently introduced by Lupin Digital Health, a wholly-owned subsidiary of the world’s largest pharmaceutical company Lupin Limited. Lyfe considerably lowers the risk of a heart attack and enhances the quality of life for cardiac patients.

83% of patients who received DTx therapies had their vital signs return to normal and stay there.
90% Medication Adherence, 90% Food and Exercise Adherence, and 0% Re-hospitalization in the Initial 30 Days.

The one-year trial was designed to assess the effectiveness of Lyfe, a digital therapeutics platform from Lupin Digital Health, on heart patients’ vital signs, medication adherence, cardiovascular events, rehospitalization, and lifestyle improvements. Patients in the program showed considerable improvement over the course of the 90-day interim analysis, and 90% of them continued to follow the prescribed medication, diet, and exercise schedule. In the first 30 days after enrollment, there were no re-hospitalizations and 83.3% of patients kept their vital signs within the normal range.

“As an interventional cardiologist, I am pleased to see such positive and encouraging preliminary findings of the trial, with more than 90% of patients following the advised medication, diet, and exercise program suggested by us. We are revolutionizing how we provide healthcare to our patients by utilizing evidence-based technology like digital medicines. While this is a great beginning, we plan to conduct in-depth clinical research and promote teamwork among all healthcare stakeholders in order to establish digital therapeutics in cardiology and realize their full potential, according to Dr. Abhijeet Palshikar, an interventional cardiac surgeon in Pune.

“We are pleased to announce the success of India’s first trial on digital therapies. The results of the study illustrate how our evidence-based, all-inclusive cardiac care program ensures high patient adherence and low rates of re-hospitalization, according to Sidharth Srinivasan, CEO of Lupin Digital Health.
enough? in the same way? in the same way? the other way, there. the other. the. With improved doctor-patient communication, ongoing health monitoring, raising patient awareness, and greater therapy adherence—all of which improve outcomes—we are committed to optimizing the patient experience.

The study’s findings suggest that, with the help of technology, digital therapeutics programs will play a significant part in patient care throughout the cardiac continuum. With the potential of digital health to enhance patients’ heart health, these findings reveal a bright future for remote patient care in cardiology.

About Lupin Digital Health

Lupin Digital Health is a fully owned subsidiary of Lupin Limited, a global pharmaceutical company, focused on developing innovative digital health solutions to address unmet patient needs. The company’s flagship product, Lyfe, is a comprehensive digital therapeutics solution that leverages artificial intelligence and machine learning to provide personalized and engaging patient experiences.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

About Publisher

IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details Click here

For more Pharma related updates Click here

Leave a Reply

Your email address will not be published. Required fields are marked *

error

Enjoy this blog? Please spread the word :)

WhatsApp
LinkedIn
Share
Follow by Email
RSS